Article Text

PDF
Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis
  1. L K Stamp1,2,
  2. J L O’Donnell1,
  3. P T Chapman1,
  4. M L Barclay3,
  5. M A Kennedy4,
  6. C M A Frampton2,
  7. R L Roberts4
  1. 1
    Department of Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
  2. 2
    Department of Medicine, University of Otago, Christchurch, New Zealand
  3. 3
    Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand
  4. 4
    Department of Pathology, University of Otago, Christchurch, New Zealand
  1. L K Stamp, Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand; lisa.stamp{at}cdhb.govt.nz

Statistics from Altmetric.com

Pharmacogenetic studies examining methotrexate (MTX) response/toxicity have focused on enzymes involved in MTX transport and folate metabolism.1 However, recently it has been reported that patients with rheumatoid arthritis (RA) with the HLA-G −/−14 bp genotype are more likely to respond to MTX.2 3 Human leukocyte antigen (HLA)-G molecules are non-classical major histocompatability complex (MHC) class I antigens that play a role in the immune system.4

We investigated whether an association exists between the HLA-G −/−14 bp polymorphism and response to MTX in a cross-sectional study of patients with RA. Of the 130 patients recruited, 75.4% were female, 81% were rheumatoid factor (RF) positive and 67% …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.